Hospitalacquired Infection Diagnostics Market Report
First published: 20 October 2024 | Last updated: 28 May 2026 | Report Code: hospitalacquired-infection-diagnostics
Hospitalacquired Infection Diagnostics Market — USD 3.5 billion in 2023, Growing to USD 6.88B by 2033 at 6.8% CAGR
This report provides a comprehensive analysis of the Hospitalacquired Infection Diagnostics market, detailing market size, growth forecasts, segmentation, regional insights, technology trends, and leading industry players for the forecast period of 2023 to 2033.
Key Takeaways
- Global market projected from $3.50 Billion in 2023 to $6.88 Billion in 2033 at a 6.8% CAGR.
- North America is largest regional market; Latin America is regional market region based on implied CAGR across 2023 to 2033.
- Latin America is identified as the regional market region, increasing from $0.01 Billion in 2023 to $0.03 Billion in 2033.
- Europe and Asia Pacific show steady expansion: Europe from $1.06 Billion to $2.08 Billion, Asia Pacific from $0.66 Billion to $1.29 Billion.
- Top firms include Roche Diagnostics, Abbott Laboratories, BD (Becton, Dickinson and Company), and bioMérieux, driving product and diagnostic innovation.
Hospitalacquired Infection Diagnostics Market Report — Executive Summary
Regional analysis shows North America as largest market and Latin America as fastest-growing region by implied CAGR. This report evaluates market growth drivers for hospital-acquired infection diagnostics, including increasing emphasis on infection control, diagnostic accuracy needs, and technology improvements. It documents a global expansion from $3.50 Billion in 2023 to $6.88 Billion by 2033 at a 6.8% CAGR for 2023 to 2033, with North America as the principal regional market and Latin America noted as the regional market region. Coverage includes segmentation by end user, test type, technology, region type, and pathogen, and profiles major players such as Roche Diagnostics, Abbott Laboratories, BD (Becton, Dickinson and Company), and bioMérieux. The analysis outlines trends toward point-of-care testing and automated systems, and identifies opportunities tied to research investments and regulatory emphasis on patient safety.
Key Growth Drivers
- Rising demand for accurate, rapid diagnostics due to infection control priorities in healthcare facilities.
- Advances in molecular and automated diagnostic platforms improving turnaround time and sensitivity.
- Increased research funding and clinical studies supporting development of novel assays and technologies.
- Regulatory and institutional focus on patient safety driving adoption of comprehensive diagnostic protocols.
- Growth in outpatient and inpatient procedures prompting greater diagnostic testing in hospitals and laboratories.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $3.50 Billion |
| CAGR (2023-2033) | 6.8% |
| 2033 Market Size | $6.88 Billion |
| Top Companies | Roche Diagnostics, Abbott Laboratories, BD (Becton, Dickinson and Company), bioMérieux |
| Published Date | 20 October 2024 |
| Last Modified Date | 28 May 2026 |
Hospitalacquired Infection Diagnostics Market Overview
Customize Hospitalacquired Infection Diagnostics Market Report market research report
- ✔ Get in-depth analysis of Hospitalacquired Infection Diagnostics market size, growth, and forecasts.
- ✔ Understand Hospitalacquired Infection Diagnostics's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Hospitalacquired Infection Diagnostics
What is the Market Size & CAGR of Hospitalacquired Infection Diagnostics Market Report market in 2023?
Hospitalacquired Infection Diagnostics Industry Analysis
Hospitalacquired Infection Diagnostics Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Hospitalacquired Infection Diagnostics Market Report Market Analysis Report by Region
Europe Hospitalacquired Infection Diagnostics Market Report:
Europe grows from $1.06 Billion in 2023 to $2.08 Billion in 2033. Regional drivers include regulatory focus on patient safety, investments in laboratory infrastructure, and growing adoption of molecular and automated testing technologies.Asia Pacific Hospitalacquired Infection Diagnostics Market Report:
Asia Pacific grows from $0.66 Billion in 2023 to $1.29 Billion in 2033. Growth in this region is supported by rising healthcare spending, expansion of diagnostic laboratories, and increased implementation of rapid testing and point-of-care solutions.North America Hospitalacquired Infection Diagnostics Market Report:
North America is largest regional market, rising from $1.32 Billion in 2023 to $2.59 Billion in 2033. The region’s expansion reflects strong hospital procurement of advanced diagnostics, emphasis on infection control protocols, and active participation of established companies and research initiatives.South America Hospitalacquired Infection Diagnostics Market Report:
Latin America is fastest-growing region by implied CAGR, increasing from $0.01 Billion in 2023 to $0.03 Billion in 2033. 01 Billion in 2023 to $0.03 Billion in 2033 and is identified as the regional growth market. Factors include increasing awareness of infection control, gradual enhancement of laboratory capabilities, and targeted investments in diagnostic tools.Middle East & Africa Hospitalacquired Infection Diagnostics Market Report:
Middle East and Africa grows from $0.46 Billion in 2023 to $0.9 Billion in 2033. Market progression is tied to improving healthcare infrastructure, a focus on infection surveillance, and adoption of more sensitive diagnostic methodologies.Tell us your focus area and get a customized research report.
Research Methodology
Hospitalacquired Infection Diagnostics Market Analysis By Test Type
The Hospital-Acquired Infection Diagnostics market is primarily segmented into molecular tests, antigen tests, and culture tests. Molecular tests dominate with a market size of $2.22 billion in 2023 and are expected to grow to $4.37 billion by 2033, holding a 63.51% market share. Antigen tests and culture tests contribute significantly, with market sizes of $0.79 billion and $0.48 billion in 2023 respectively, both growing similarly over the forecast period. This reflects a growing preference for rapid and precise testing methodologies among healthcare providers.
Hospitalacquired Infection Diagnostics Market Analysis By Pathogen Type
In pathogen-type segmentation, diagnostics for bacteria account for the largest share, representing $2.22 billion in 2023, with a steady increase to $4.37 billion by 2033. The demand for virus and fungi diagnostics, estimated at $0.79 billion and $0.48 billion respectively in 2023, is also on an upward trend as healthcare entities seek to comprehensively manage HAIs, resulting in a balanced approach to pathogen identification.
Hospitalacquired Infection Diagnostics Market Analysis By Technology
The technology segment reveals a strong inclination towards automated diagnostic systems, which commanded an impressive market size of $2.93 billion in 2023 and is set to grow to $5.75 billion by 2033, accounting for 83.58% of the market share. Point-of-care testing is smaller but gaining traction, moving from $0.57 billion to $1.13 billion over the forecast period, signifying healthcare's shift towards rapid and accessible testing solutions.
Hospitalacquired Infection Diagnostics Market Analysis By End User
Hospitals lead the market for hospital-acquired infection diagnostics, projected to grow from $2.22 billion in 2023 to $4.37 billion by 2033. Diagnostic laboratories and academic research institutions follow, with expected values of $0.79 billion and $0.48 billion respectively in 2023. This segmentation illustrates hospitals' reliance on diagnostics to enhance patient safety through effective infection management.
Hospitalacquired Infection Diagnostics Market Analysis By Region Type
Market performance varies significantly by region, with North America leading by a substantial margin. The projected growth rates in Europe and Asia-Pacific are noteworthy, reflecting a strengthening focus on infection control globally. Emerging markets in South America and the Middle East and Africa are also expanding, though they face infrastructural and regulatory challenges.
Hospitalacquired Infection Diagnostics Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Hospitalacquired Infection Diagnostics Industry
Roche Diagnostics:
Roche Diagnostics is a leader in the healthcare industry, providing innovative diagnostic solutions aimed at improving overall patient care and outcomes. Their advanced molecular tests are pivotal in HAI detection and management.Abbott Laboratories:
Abbott Laboratories is renowned for its diverse range of diagnostic products, particularly in point-of-care testing and molecular diagnostics, providing highly accurate results for hospital-acquired infections.BD (Becton, Dickinson and Company):
BD is a global medical technology company that advances the world of health by improving medical discovery, diagnostics, and the delivery of care with their portfolio of infection diagnostics solutions.bioMérieux:
bioMérieux specializes in in vitro diagnostics and offers a comprehensive range of solutions for the rapid detection of pathogens and monitoring antibiotic resistance.We're grateful to work with incredible clients.
FAQs
What is the market size of the Hospitalacquired Infection Diagnostics Market Report in 2023?
The market size for 2023 is $3.50 Billion, as stated in the provided data for the Hospitalacquired Infection Diagnostics Market Report.
How big is the market expected to be in 2033?
The market is projected to reach $6.88 Billion by 2033, according to the forecast figures supplied for the report.
What is CAGR for the forecast period?
The reported compound annual growth rate (CAGR) for 2023 to 2033 is 6.8%, based on the input data supplied for the market.
Which region is the fastest Growing in the Hospitalacquired Infection Diagnostics Market Report market?
Latin America is the fastest-growing region, projected to expand from $0.01 Billion in 2023 to $0.03 Billion in 2033, reflecting an implied 11.61% CAGR over the forecast period.
Which region is the fastest Growing?
Latin America is stated as the regional market region, rising from $0.01 Billion in 2023 to $0.03 Billion in 2033 at an implied 11.61% CAGR.
Who are the top companies in this market?
Top companies listed in the input are Roche Diagnostics, Abbott Laboratories, BD (Becton, Dickinson and Company), and bioMérieux.
Why are diagnostics advancing in this sector?
Diagnostics are advancing due to heightened infection control focus, technological improvements in testing platforms, and increased research investments supporting improved accuracy and speed.
What end User segments are included?
Reported end-user subsegments include Hospitals, Diagnostic Laboratories, and Academic and Research Institutions as specified in the input.
Which test types are covered in the segmentation?
The segmentation specifies Molecular Tests, Antigen Tests, and Culture Tests as the included test-type subsegments.
How is the market analyzed by technology?
By-technology subsegments provided are Automated Diagnostic Systems and Point-of-Care Testing, reflecting technology-driven differentiation in diagnostics.